How we built this comparison
Before any provider was added, we set the criteria we’d compare on — the same discipline we use for every commercial comparison on this site, described in full in our Editorial Policy:
- Access model — whether the provider prescribes FDA-approved brand-name medications only, offers compounded alternatives, or operates as an open marketplace of independent clinicians.
- Prescriber type — who actually evaluates you and writes the prescription.
- Insurance versus cash-pay — whether the service is built around billing insurance or around a flat cash price.
- Pricing structure — membership or programme fees, separated from medication cost, exactly as each provider itself discloses it. Those two figures are what most comparisons collapse into one, so we also add them back together and price every provider here against buying direct from the manufacturer.
- State coverage — reported where the provider publishes it; marked “not published” where it doesn’t, rather than guessed.
- Compounding disclosure and regulatory flags — anything publicly reported that a reasonable person would want to know before paying, including active litigation.
We have not personally used any of these services, so we are not rating quality of care, wait times, or customer service — we report what each provider publishes about itself, cross-checked against independent reporting where we found it, with a date and a source for every field. This list is not exhaustive; it covers providers with a clear public pricing and terms page as of the verification date below.
One field on every record here is worth reading before the price: which molecule a provider actually names. Several advertise “a GLP-1” at a figure without ever saying which drug it is, so we file providers by molecule only where their own wording does — the providers that name semaglutide and the smaller number that name tirzepatide are costed separately for that reason, and the ones that name neither are listed as exactly that rather than assigned to whichever page had room.
Those are the axes we compare on. The separate question — what a provider has to satisfy before it appears here at all, and which of those requirements we actually verify rather than merely require — is set out in the full listing standard, including the four things we do not check.
A directory is the wrong shape for a reader who has not yet worked out what would rule a provider out, which for most people is settled before quality is in question. Narrowing fifteen services down to the two or three you can actually use works through those filters in order, and counts how much of each one the category publishes.
Terms move. Where a price has risen, a service has been withdrawn, or a provider has been named in litigation since we last wrote about it, that is recorded with a date and a source in the log of what changed and when — along with the times our own check of a provider turned out to be wrong.
How often we re-check, and what that means
Everything above is a snapshot of what each provider published on a date, and this category moves fast — prices change, states get added and dropped, and regulatory positions shift. A directory whose verification dates never move is not a verified directory, so we publish the schedule rather than a promise to keep things current.
- Last full sweep
- 2026-09-10
- Re-checked every
- 30 days
- Next sweep due
- 2026-10-10
- Records in this directory
- 15
If the date above has passed, this page is overdue and you should treat every figure on it as needing confirmation before you act on it. We would rather publish a date you can hold us to than a claim that everything is current.
Each sweep is written up rather than silently applied. The latest is the September 2026 provider sweep, which found two prices moved, one figure of ours wrong by $29 a month, and two we could not re-confirm at all. Before it, the August sweep.
A sweep re-reads, for every provider:
- the provider's own pricing page, for the cash price and any membership fee billed separately
- the terms page, for what the fee covers and what renews
- the states-served list, where the provider publishes one
- whether the product is brand-name or compounded, in the provider's own words
- FDA, FTC and state attorney-general actions, and any active litigation
6 records did not make the last sweep. Their dates are older than the sweep date above, so treat them as the least current entries here. In every case the reason is the same shape: the provider’s price is no longer on a page that can be read without running its code or handing over your details first. We have left the old figures and the old date rather than re-dating something we did not actually re-read.
- Hims & Hers (last verified 2026-07-26) — hims.com returned HTTP 403 to every request from us on 11 August 2026 and again on 10 September 2026, so nothing on this record has been re-read against the source since July. Two consecutive sweeps have now failed the same way, which makes this a standing block rather than an outage.
- Sesame (last verified 2026-08-11) — Partially re-read on 10 September 2026. The $34 visit floor and the $149 Wegovy pill price were confirmed on sesamecare.com, but the $249 'Success by Sesame' figure appeared nowhere and the weight-loss URL we would check it against returns 404. The programme price is the figure a cost comparison depends on, so this record is not treated as re-verified.
- Delilah (last verified 2026-07-26) — joindelilah.com served us its page on 11 August 2026 and again on 10 September 2026 — 189KB of markup, about 12,000 characters of readable text, and no price in either read. The figures are drawn in by the browser after the page loads, so there is nothing to re-read.
- Fella Health (last verified 2026-07-26) — On 11 August 2026 and again on 10 September 2026 Fella's site published prices for its add-on longevity treatments ($45–$149/month) but no price for the GLP-1 programme itself, which sits behind an eligibility quiz. A /pricing URL returns 404. There is no public page left to check our figures against.
- Henry Meds (last verified 2026-07-26) — henrymeds.com served us half a megabyte on 11 August 2026 and the same again on 10 September 2026 — about 15,000 characters of readable text, and not one figure in it. The prices are assembled in the browser.
- Willow Health (last verified 2026-07-26) — willowhealth.com returned a near-empty shell on 11 August 2026 and on 10 September 2026 — 701 characters of readable text both times, and no price. Worth noting for anyone re-checking: the September response was 79KB, which looks like a substantial page until the markup is stripped. Byte count is not content.
Prices in particular are the field most likely to be wrong first. Whatever a provider is charging today is on its own pricing page, and that page is the authority — not this one.
The compounding rules are changing — here's the nuance most sites skip
Compounded semaglutide and tirzepatide became widely available during 2022–2024 while the brand-name versions were on the FDA's drug shortage list, which temporarily let outsourcing facilities compound copies. Semaglutide came off that shortage list in 2025 and tirzepatide in 2024.
On 30 April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the '503B bulks list' — the mechanism that lets large outsourcing facilities compound a drug at scale without an individual prescription in hand. If finalised, this would end large-scale compounded supply from that channel. The comment period was extended and closed 30 July 2026; a final decision is still pending. The dates and sources are on our update about the proposal.
This does not ban compounding outright. Traditional '503A' pharmacies — which compound to fill an individual, patient-specific prescription under state pharmacy board oversight — operate under a separate legal provision and are not directly affected by the 503B proposal. This is why some providers below can still legally offer compounded products even as the bulk-supply channel narrows.
Separately from the shortage rules, Eli Lilly has sued several telehealth companies (see the flags on individual listings below) alleging that some compounded products were marketed deceptively, including undisclosed additives not present in the approved drug. One of those cases (Willow Health) was dismissed in September 2025; the others remained active as of mid-2026. A lawsuit is an allegation, not a finding of fact — but it's a live legal dispute worth knowing about before you buy.
Verified 2026-07-26 against U.S. Food & Drug Administration; MobiHealthNews; Lengea Law.
This page compares companies, which is the right shape once you know you want a telehealth provider. If you have not got that far — if the question is still where a prescription comes from at all — the four decisions every route runs through is the page that comes before this one.
Which one is best? Why this page will not tell you
It is the most-asked version of this question and it has an uncomfortable answer here. This site intends to earn flat referral fees from the companies listed above. A ranking published by a site the ranked companies pay is a price list wearing a lab coat, and a flat fee does not fix that — it protects against selling first place, not against choosing the criteria that happen to put a payer there.
So the ordering is deliberately not ours to give. What we can do is hand over the decision, because “best” is not one property — it decomposes into four that genuinely differ across these 15 companies, and which one matters is a fact about you rather than about them:
- What they can prescribe. The 4 access models above are not a stylistic difference. A brand-name-only service cannot supply a compounded preparation and a compounded-only service cannot supply an approved product, so this choice is made before any other.
- Whether insurance is in play. 6 of 15 work with insurance in some form; the rest are cash-pay. If you have coverage that includes a GLP-1, that single fact outweighs every price on this page.
- How the fee is charged. A membership recurs whether or not anything happens that month, which is a different shape of cost from a per-visit fee — and two national pharmacy chains now charge the second kind.
- Who actually evaluates you. The prescriber column varies more than the marketing does, from named physicians to whichever independent clinician a marketplace surfaces.
The matching tool above sorts on your answers to exactly those questions rather than on ours. What follows is the same thing without the tool: each situation people actually mean by “best”, and every provider above whose own published terms fit it.
Best for what, exactly
These are filters, not places. A provider appearing under four of them is not beating one that appears under a single filter — the criteria are alternatives, and only one of them is likely to be yours. Within each, providers are listed alphabetically, and no provider in the directory satisfies every criterion — the build fails if one ever does, because that would be a ranking with a winner arrived at by accident.
- You have insurance that may cover a GLP-1
Amazon One Medical, Calibrate, Found, Noom Med, PlushCare, Ro (Body) — 6 of 15.
Selects providers whose own published terms describe billing or working with insurance. It says nothing about whether your particular plan covers anything — only that the provider is set up to try.
- You want an FDA-approved product and nothing else
Amazon One Medical, Calibrate, Hims & Hers, PlushCare, Ro (Body), WeightWatchers Clinic — 6 of 15.
Selects providers that prescribe only approved brand-name medications and do not advertise compounded preparations, so the question of compounding never arises.
- You want coaching or dietitian support included
Alloy, Calibrate, Delilah, Fella Health, Found, Noom Med, WeightWatchers Clinic — 7 of 15.
Selects providers that bundle behavioural support into the standard offer rather than selling the prescription alone. Whether bundled support is worth its price is not something we can tell you.
- You want a provider with no caution on its record here
Alloy, Amazon One Medical, Calibrate, Found, Hims & Hers, Noom Med, PlushCare, Ro (Body), Sesame, WeightWatchers Clinic — 10 of 15.
Selects providers carrying no caution-level flag — no open litigation and no unresolved regulatory issue that our sweeps have recorded. A clean record is the absence of a finding, not a finding of quality.
- You want care built around a specific population
Alloy, Delilah, Fella Health — 3 of 15.
Selects providers that position themselves around one group in their own words — menopause, women's health, men's health. It is their claim about their focus, not our assessment of how well they serve it.
Read the row for whichever of those is your situation and the shortlist is usually two or three companies, which is a decision you can finish. That is as close to “best” as this page will get, and it is a better answer than a number we assigned.
How to tell a legitimate provider from one that is not
A more useful question than which is best, and one with checkable answers. Every company above clears the bar set out in the standard a listing has to meet, and the same tests work on any provider you find elsewhere:
- It requires a real evaluation before prescribing. Not a questionnaire that approves everyone. If nothing you could answer would result in a refusal, nobody is assessing you.
- It says who prescribes and under what licence. Vagueness here is the single most reliable warning sign.
- It publishes its own terms where you can read them. Several of the companies above failed that test on our last sweep, and the profiles say so rather than quietly carrying an older figure.
- It does not sell you a prescription medicine without one. Anything labelled “for research use only” while arriving with dosing instructions is not a provider at all.
What we didn’t include, and why
Every provider above requires a genuine medical evaluation before prescribing. We deliberately left out sites that dispense GLP-1 products — compounded or otherwise — without one: no-prescription “research chemical” sellers and international pharmacies operating outside U.S. licensing. Including those, even with a caution label, would put them on a page designed to look trustworthy, which is precisely what our Medical Disclaimer warns against.
We also left out tools like GoodRx that don’t themselves evaluate or prescribe — they’re price-comparison and pharmacy-discount services, a different category from a telehealth provider, and belong in a future guide of their own rather than this directory.
Within the providers we did include, coverage is deliberately broad: brand-name-only services, hybrid brand-plus-compounded platforms, an open marketplace, and cash-pay compounded-only services — including several currently facing litigation or regulatory challenges, clearly labelled rather than omitted. If a legitimate provider is missing, or something here is out of date, tell us at our contact page and we’ll check it.
Common questions
- Who are the best GLP-1 providers?
- We deliberately do not rank them, because this site intends to earn flat referral fees from the companies listed — and a ranking published by a site the ranked companies pay is a price list, whatever it is called. What the page answers instead is "best for what": 5 situations people mean by the question, each one a single published fact, with every provider that fits it named. If you have insurance that may cover a GLP-1, 6 of the 15 are set up to bill it. If you want an FDA-approved product and nothing compounded, 6 prescribe only those. Whichever of those is your situation, the shortlist is two or three companies rather than all 15 — and no provider in the directory satisfies all 5 criteria, which is why there is no single winner to name.
- Which are the best online GLP-1 providers?
- Every provider in this directory is online — telehealth is the scope of the page, so "online" narrows nothing here and the question collapses back into which one fits you. What does narrow it is that telehealth companies are licensed state by state, so the practical first filter is which ones operate where you live. The alternative to online is a retail pharmacy visit or your own doctor, both of which are covered elsewhere on this site.
- How do I know a GLP-1 provider is legitimate?
- Four checkable tests. It requires a real medical evaluation rather than a questionnaire that approves everyone. It states who prescribes and under what licence. It publishes its own terms somewhere you can read them. And it never supplies a prescription medicine without a prescription — anything labelled 'for research use only' while arriving with dosing instructions is not a provider.
- Which GLP-1 providers take insurance?
- 6 of the 15 in this directory work with insurance in some form, and the rest are cash-pay. The distinction matters more than any price on the page: if you have coverage that includes a GLP-1, that single fact usually outweighs every membership fee and cash rate listed here. Each profile records what the company itself publishes about insurance, with the date we read it.
- Are there GLP-1 providers with no membership fee?
- Not among the telehealth companies in this directory — all of them charge a recurring fee of some kind. The no-membership options are elsewhere: buying direct from a manufacturer, using a savings card through your own pharmacy, and the two national pharmacy chains that now prescribe for a per-visit fee instead.
- Are there GLP-1 providers near me?
- Almost certainly, but locality matters less than it feels like it should for a mail-order weekly injection. What locality does decide is availability: telehealth companies are licensed state by state, and compounded products are unavailable in several states. Each profile records the states a provider says it serves.
- How is this different from the 'best GLP-1 provider' lists elsewhere?
- Most published lists are either affiliate-ranked or graded on criteria the author chose without saying so. This one is unranked by design, states its own commercial arrangement on the page, sets the comparison criteria before the providers were added, and re-reads every company's published terms on a schedule — publishing the checks that failed alongside the ones that passed.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.